Fiche centre
Optimal Clinical Trials
Auckland — New Zealand
Essais liés6clinical trials
VilleAucklandlocalisation
PaysNew Zealandlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06077864
Essais cliniques associés
6| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Survodutide | Maladie rénale chronique | Phase 3 | NCT06077864 | A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) | COMPLETED |
| Sevasemten 10 mg | Myopathies | Phase 2 | NCT05291091 | Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) | COMPLETED |
| Sevasemten | Myopathies | Phase 2 | NCT06066580 | MESA — Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy | ENROLLING_BY_INVITATION |
| KER-065 | Myopathies | Phase 2 | NCT07704099 | Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy | RECRUITING |
| Corabotase | Migraine | Phase 2 | NCT06625060 | MERANTI — A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults | ACTIVE_NOT_RECRUITING |
| Ocrelizumab IV | SEP | Phase 3 | NCT05232825 | Ocarina II — A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis | COMPLETED |